GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Forward PE Ratio

Shanghai Henlius Biotech (HKSE:02696) Forward PE Ratio : 16.92 (As of May. 29, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Forward PE Ratio?

Shanghai Henlius Biotech's Forward PE Ratio for today is 16.92.

Shanghai Henlius Biotech's PE Ratio without NRI for today is 16.44.

Shanghai Henlius Biotech's PE Ratio for today is 17.33.


Shanghai Henlius Biotech Forward PE Ratio Historical Data

The historical data trend for Shanghai Henlius Biotech's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Forward PE Ratio Chart

Shanghai Henlius Biotech Annual Data
Trend 2022-07 2023-12 2024-05
Forward PE Ratio
21.23 7.69 16.92

Shanghai Henlius Biotech Quarterly Data
2022-03 2022-06 2023-09 2023-12 2024-03
Forward PE Ratio 24.33 20.37 6.97 7.69 11.83

Competitive Comparison of Shanghai Henlius Biotech's Forward PE Ratio

For the Biotechnology subindustry, Shanghai Henlius Biotech's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Henlius Biotech's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Shanghai Henlius Biotech's Forward PE Ratio falls into.



Shanghai Henlius Biotech Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Shanghai Henlius Biotech  (HKSE:02696) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Shanghai Henlius Biotech Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Henlius Biotech (HKSE:02696) Business Description

Traded in Other Exchanges
N/A
Address
No. 1801 Hongmei Road, 9th Floor, Innov Tower (Capitaland Building), Xuhui District, Shanghai, CHN, 200233
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
Executives
Qatar Investment Authority 2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited 2101 Beneficial owner
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 2201 Interest of corporation controlled by you
Fosun Holdings Limited 2201 Interest of corporation controlled by you
Fosun International Holdings Ltd. 2201 Interest of corporation controlled by you
Fosun International Limited 2201 Interest of corporation controlled by you
Guo Guangchang 2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd. 2201 Interest of corporation controlled by you
Liu Scott Shi-kau 2201 Interest of corporation controlled by you
Jiang Wei-dong 2201 Interest of corporation controlled by you
Henlius Biopharmaceuticals, Inc. 2101 Beneficial owner

Shanghai Henlius Biotech (HKSE:02696) Headlines

No Headlines